other material
confidence high
sentiment positive
materiality 0.85
Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%
RELMADA THERAPEUTICS, INC.
- Oversubscribed PIPE financing of ~$160M gross from 29.47M shares at $4.75/share plus pre-funded warrants, expected to close March 11, 2026.
- Proceeds to be used for working capital and advancing R&D of product candidates, including NDV-01.
- NDV-01 Phase 2 in high-risk NMIBC: 12-month complete response rate 76% overall, 80% in BCG-unresponsive patients.
- No Grade 3+ treatment-related adverse events; no patient progressed to muscle-invasive disease or required cystectomy.
- Phase 3 RESCUE program planned for mid-2026 with two registrational pathways: 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC.